

Page 31, line 26: after "YSFKPMPLaR" insert --(SEQ ID NO:1)--.

Page 31, line 27: after "YKQGGFLGLYSFKPMPLaR" insert --(SEQ ID NO:2)--.

Page 31, line 31: after "YSFKPMPLaRKQGGFLGL" insert --(SEQ ID NO:5)--.

Page 36, line 36: after "K-Ahx-YSFKPMPLaR" insert --(SEQ ID NO:8)--.

Page 37, line 12: before "and" insert --(SEQ ID NO:8)--.

Page 38, line 36: before "covalently" insert --(SEQ ID NO:9)--.

Page 39, line 1: after "(YSFKPMPLaR)" insert --(SEQ ID NO:1)--.

Page 39, line 7: before "construct" insert --(SEQ ID NO:10)--.

Page 47, line 29: before "and" insert --(SEQ ID NO:2)--.

Page 47, line 32: after "KLH" insert --(SEQ ID NO:6)--.

Page 48, line 1: before "and" insert --(SEQ ID NO:9)--.

Page 48, line 2: after "GDLSDPGCGNRTNLGGRDSL" insert --(SEQ ID NO:11)--.

After the last page of the specification, and before the first page of claims, please insert the paper copy of the Sequence Listing submitted herewith.

In the claims:

B2 18. (Amended) A method for enhancing an [activating an antigen presenting cell for inducing an enhanced] immune response to an immunogen by activating an antigen presenting cell, [said immunogen being delivered to the antigen presenting pathway of said antigen presenting cell,] said method comprising binding to a characteristic surface determinant of said antigen presenting cell a molecular adjuvant [as claimed in claim 1] comprising a targeting ligand having binding affinity for said characteristic determinant, said targeting ligand being functionally linked to

B²
said immunogen, said binding activating said antigen presenting cell and effecting delivery of said immunogen to an antigen presenting pathway of said antigen presenting cell, thereby enhancing said immune response.

B³
22. (Amended) The method of claim 18, adapted [A method] for eliciting an antigen presenting cell-mediated immune response in a host susceptible to infection by an antigen containing disease causing agent, said method comprising administering to said individual said [a] molecular adjuvant, [as claimed in claim 1], wherein said immunogen comprises the antigen of said disease causing agent, in an amount effective for eliciting said immune response.

23. (Amended) The method of claim 18, adapted [A method] for eliciting an immune response to a tumor-associated antigen, said method comprising administering to a host having a tumor expressing said tumor-associated antigen said [a] molecular adjuvant [as claimed in claim 1], wherein said immunogen comprises said tumor-associated antigen, in an amount effective for eliciting said immune response.

Claim 24, line 3: change "immunogenic" to --immunogenically--;

Claim 24, line 5: change "form" to --from--.

Please add the following new claim:

B⁴ 25. Antibodies produced by the method of claim 24.

REMARKS

The specification has been amended to provide the patent number of now-issued U.S. Application No. 08/299,285, and to enter a Sequence Listing and provide Sequence I.D. Numbers in